Researchers published the study covered in this summary on researchsquare.com as a preprint that has not yet been peer reviewed. Study participants had no clinical fractures during 24 months of follow ...

Subsequent denosumab doses were associated with lower risks for hypocalcemia among patients with osteoporosis and chronic kidney disease . Magnitude of serum calcium decrease is smaller with ...

The US Food and Drug Administration (FDA) issued an alert today that cited preliminary evidence for a "substantial risk" for severe and symptomatic hypocalcemia and serious outcomes related to ...

The FDA has added a serious warning to the prescribing information for Amgen Inc’s (NASDAQ:AMGN) drug Prolia (denosumab), emphasizing an increased risk of severely low calcium levels in specific ...

Please provide your email address to receive an email when new articles are posted on . The FDA is investigating the risk of severe hypocalcemia in patients on dialysis treated with the osteoporosis ...

Findings showed treatment with Prolia significantly increased the risk of developing severe hypocalcemia compared with bisphosphonates, especially in patients with advanced CKD. In patients with ...

An Amgen sign is seen at the company's office in South San Francisco (Reuters) - The U.S. Food and Drug Administration added a serious warning on the prescribing information for Amgen's drug Prolia to ...